PathAI, GSK partner to accelerate research, drug development

By The Science Advisory Board staff writers

April 5, 2022 -- PathAI and GlaxoSmithKline (GSK) have announced a strategic multiyear partnership to accelerate scientific research and drug development programs in oncology and non-alcoholic steatohepatitis (NASH).

Under the agreement, GSK will gain access to PathAI's technologies in digital pathology, including its artificial intelligence-based measurement of NASH (AIM-NASH) tool, which provides AI-based NASH scoring.

The companies said that the partnership will combine GSK's and PathAI's AI and platform engineering teams to scale algorithm development and enable the discovery of new insights that can be integrated into clinical trials.

Akoya Biosciences, PathAI collaborate on novel predictive biomarkers
Akoya Biosciences is collaborating with PathAI to advance the discovery and validation of novel predictive biomarkers for immunotherapies. The collaboration...
PathAI, Summit Clinical partner for NASH trial services
PathAI recently entered a partnership with Summit Clinical Research to launch a clinical trial services solution for developers of drugs to treat nonalcoholic...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter